Marker Therapeutics Accounts Payables 2011-2026 | MRKR

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Marker Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
794 K	1.07 M	961 K	1.61 M	5.14 M	2.94 M	993 K	1.62 M	1.02 M	680 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.14 M	680 K	1.68 M

Quarterly Accounts Payables Marker Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
951 K	1.72 M	1.3 M	1.07 M	1.9 M	1.08 M	1.2 M	961 K	1.16 M	1.33 M	2.86 M	1.1 M	2.02 M	1.77 M	5.02 M	5.14 M	2.33 M	2.04 M	1.89 M	2.94 M	2.94 M	2.94 M	2.94 M	993 K	993 K	993 K	993 K	1.62 M	1.62 M	1.62 M	1.62 M	1.02 M	-	-	688 K	680 K	-	-	680 K	691 K	-	-	-	693 K	671 K	-	-	3.78 M	3.78 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.14 M	671 K	1.79 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Verastem VSTM	12.4 M	$ 5.04	-4.73 %	$ 349 M	USA
VistaGen Therapeutics VTGN	653 K	$ 0.57	-5.87 %	$ 17.6 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Aileron Therapeutics ALRN	3.98 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	724 K	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	155 K	-	-52.27 %	$ 4.45 M	USA
Adaptive Biotechnologies Corporation ADPT	6.47 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Xenon Pharmaceuticals XENE	5.07 M	$ 54.48	-1.89 %	$ 4.24 B	Canada
BeiGene, Ltd. BGNE	479 M	-	0.49 %	$ 251 B	Cayman-islands
ChemoCentryx CCXI	6.75 M	-	-	$ 3.74 B	USA
Enochian Biosciences ENOB	12.6 M	-	-	$ 40.5 M	USA
Summit Therapeutics SMMT	20.3 M	$ 16.58	-3.94 %	$ 12.4 B	Britain
Bellerophon Therapeutics BLPH	1.23 M	-	-74.18 %	$ 955 K	USA
Alnylam Pharmaceuticals ALNY	116 M	$ 317.36	-3.29 %	$ 41.6 B	USA
Arbutus Biopharma Corporation ABUS	1.17 M	$ 4.29	-3.6 %	$ 822 M	Canada
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	406 K	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	1.03 M	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	3.65 M	-	-10.95 %	$ 876 K	USA
Fusion Pharmaceuticals FUSN	1.86 M	-	-	$ 1.41 B	Canada
Ampio Pharmaceuticals AMPE	750 K	-	-11.43 %	$ 502 K	USA
AlloVir ALVR	1.28 M	-	4.14 %	$ 49.1 M	USA
Amphastar Pharmaceuticals AMPH	32.6 M	$ 19.01	-2.66 %	$ 889 M	USA
Gritstone Oncology GRTS	3.82 M	-	0.42 %	$ 213 M	USA
ACADIA Pharmaceuticals ACAD	16.2 M	$ 20.75	-3.35 %	$ 3.44 B	USA
Aligos Therapeutics ALGS	3.98 M	$ 6.66	-5.4 %	$ 65.8 M	USA
Aravive ARAV	8.76 M	-	-13.39 %	$ 1.45 M	USA
Alkermes plc ALKS	108 M	$ 29.39	-1.77 %	$ 4.84 B	Irlanda
Cabaletta Bio CABA	6.64 M	$ 2.68	-4.96 %	$ 269 M	USA
AbbVie ABBV	3.59 B	$ 209.4	-0.81 %	$ 370 B	USA
ARCA biopharma ABIO	3.46 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	3.81 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	601 K	-	4.01 %	$ 150 M	Canada
Athira Pharma ATHA	319 K	-	-	$ 269 M	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA